RHI
54
-5
AA
53
-3
INTC
36
-5
CAT
62
-3
PSX
50
-2
PYPL
50
-6
AIV
67
-5
NUE
58
-2
INTU
56
3
DLTR
44
-2
A
41
-2
DUK
54
-3
DD
60
-7
VRTX
52
-2
ITW
65
-5
NSC
60
-2
AIZ
80
2
AVB
59
-3
ALL
45
-3
GIS
35
-2
RHI
54
-5
AA
53
-3
INTC
36
-5
CAT
62
-3
PSX
50
-2
PYPL
50
-6
AIV
67
-5
NUE
58
-2
INTU
56
3
DLTR
44
-2
A
41
-2
DUK
54
-3
DD
60
-7
VRTX
52
-2
ITW
65
-5
NSC
60
-2
AIZ
80
2
AVB
59
-3
ALL
45
-3
GIS
35
-2
Financhill
Back

Janux Therapeutics 10K Form

Sell
34

JANX
Janux Therapeutics

Last Price:
67.68
Seasonality Move:
133.13%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive JANX News And Ratings

See the #1 stock for the next 7 days that we like better than JANX

JANX Financial Statistics

Sales & Book Value

Annual Sales: $8.08M
Cash Flow: $-2.26M
Price / Cash Flow: 0
Annual Sales: $12.54
Price / Book: 4.79

Profitability

EPS (TTM): -1.16000
Net Income (TTM): $-60.54M
Gross Margin: --
Return on Equity: -11.37%
Return on Assets: -10.65%

Janux Therapeutics Earnings Forecast

Key Janux Therapeutics Financial Ratios

  • The Research & Development expenses have been 679.48% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of JANX is -721.18% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 2 years.

Janux Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: JANX
Website: januxrx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 38.8
Quick Ratio: 38.58

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

JANX Technical Analysis vs Fundamental Analysis

Sell
34
Janux Therapeutics (JANX) is a Sell

Is Janux Therapeutics a Buy or a Sell?